Literature DB >> 10952127

Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.

R F Ozols1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10952127

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  8 in total

1.  A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.

Authors:  Béatrice Weber; Rémy Largillier; Isabelle Ray-Coquard; Gabriel Yazbek; Jérôme Meunier; Jérôme Alexandre; Jérôme Dauba; Dominique Spaeth; Rémy Delva; Florence Joly; Eric Pujade-Lauraine; Laure Copel
Journal:  Support Care Cancer       Date:  2013-02-19       Impact factor: 3.603

2.  Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.

Authors:  A García-Velasco; C Mendiola; A Sánchez-Muñoz; C Ballestín; R Colomer; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

3.  Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.

Authors:  Nuo Yang; Jia Huang; Joel Greshock; Shun Liang; Andrea Barchetti; Kosei Hasegawa; Sarah Kim; Antonis Giannakakis; Chunsheng Li; Anne O'Brien-Jenkins; Dionyssios Katsaros; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

4.  Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.

Authors:  Dimitra T Stefanou; Aristotelis Bamias; Hara Episkopou; Soterios A Kyrtopoulos; Maria Likka; Theodore Kalampokas; Stylianos Photiou; Nikos Gavalas; Petros P Sfikakis; Meletios A Dimopoulos; Vassilis L Souliotis
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

5.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

6.  Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

Authors:  G D'Agostino; G Ferrandina; M Ludovisi; A Testa; D Lorusso; N Gbaguidi; E Breda; S Mancuso; G Scambia
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

7.  Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Authors:  Katy Milne; Rebecca O Barnes; Adam Girardin; Melanie A Mawer; Nancy J Nesslinger; Alvin Ng; Julie S Nielsen; Robert Sahota; Eric Tran; John R Webb; May Q Wong; Darin A Wick; Andrew Wray; Elissa McMurtrie; Martin Köbel; Steven E Kalloger; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2008-10-15       Impact factor: 3.240

8.  Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.

Authors:  John Wahba; Marina Natoli; Lynsey M Whilding; Ana C Parente-Pereira; Youngrock Jung; Stefania Zona; Eric W-F Lam; J Richard Smith; John Maher; Sadaf Ghaem-Maghami
Journal:  Cancer Immunol Immunother       Date:  2018-08-24       Impact factor: 6.968
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.